Pasithea Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
PAS-004 is being tested in NF1, where cutaneous lesions have substantial unmet need and no approved systemic treatment. Initial Phase Ib data are expected next month, with dose selection for expansion targeted around Q1 or Q2 next year.
-
The meeting approved the election of two directors, ratified the independent auditors, and authorized a reverse stock split at a flexible ratio. No questions were raised, and all proposals passed by majority vote.
-
PAZ004, a macrocyclic MEK inhibitor, is advancing through clinical trials for NF1 and advanced cancers, showing a differentiated safety and PK profile with promising early efficacy. The program targets significant unmet needs, especially in cutaneous neurofibroma, and is supported by strong patent protection and recent financing.